Dublin, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2034" report has been added to ResearchAndMarkets.com's offering. This ...

An announcement from Century Therapeutics ( ($IPSC) ) is now available. On December 18, 2025, Century Therapeutics, Inc. announced that board ...

Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that ...

Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in Combination with Daratumumab Preclinical Data under ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks ...

Colossal scientists achieve global first; technology promises seminal advancements for engineering Woolly Mammoth phenotypes in in vitro cellular models, developmental biology, and attaining balance ...

In this interview, we speak to Keith Olson and Coby Carlson from FUJIFILM Cellular Dynamics about their iPSC technology and how it is making breakthroughs in blood-brain barrier research. Please can ...

Cellino, a biotechnology firm working on autonomous biomanufacturing for personalized regenerative medicines, has signed a strategic collaboration with Karis Bio, a South Korean cell therapy company, ...

A multi-institutional group, including members of the Tau Consortium, unveiled a stem cell tool kit for scientists studying primary tauopathies. In the November 12 issue of Stem Cell Reports, ...

IPSC was founded in 1977 and has grown rapidly over the past 30 years. With over 800 employees, IPSC is a multi-divisional firm. IPSC installs high quality security systems for residential and ...